Boston Scientific Files 8-K on Financials

TL;DR

BSX filed an 8-K on Oct 22, 2025, covering financial results and condition.

AI Summary

Boston Scientific Corporation filed an 8-K on October 22, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details information related to its common stock and senior notes due in 2027.

Why It Matters

This filing provides investors with updated information on Boston Scientific's financial performance and condition, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

• Boston Scientific Corporation (company) — Registrant
• October 22, 2025 (date) — Filing Date
• 300 Boston Scientific Way, Marlborough, Massachusetts (address) — Business Address

FAQ

From the Filing

0000885725-25-000046.txt : 20251022 0000885725-25-000046.hdr.sgml : 20251022 20251022063246 ACCESSION NUMBER: 0000885725-25-000046 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20251022 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251022 DATE AS OF CHANGE: 20251022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 251408556 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20251022.htm 8-K bsx-20251022 0000885725 false 0000885725 2025-10-22 2025-10-22 0000885725 us-gaap:CommonStockMember 2025-10-22 2025-10-22 0000885725 bsx:SeniorNotedue2027Member 2025-10-22 2025-10-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): October 22, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of Principal Executive Offices)                           (Zip Code) 508 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 22, 2025, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of th